266 related articles for article (PubMed ID: 11602651)
1. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
2. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Song S; Wientjes MG; Walsh C; Au JL
Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Song S; Wientjes MG; Gan Y; Au JL
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8658-63. PubMed ID: 10890892
[TBL] [Abstract][Full Text] [Related]
4. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.
Xin Y; Lyness G; Chen D; Song S; Wientjes MG; Au JL
J Urol; 2005 Jul; 174(1):322-7. PubMed ID: 15947683
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
[TBL] [Abstract][Full Text] [Related]
6. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Song S; Yu B; Wei Y; Wientjes MG; Au JL
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6058-65. PubMed ID: 15447990
[TBL] [Abstract][Full Text] [Related]
7. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Chen CT; Gan Y; Au JL; Wientjes MG
Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
9. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
[TBL] [Abstract][Full Text] [Related]
11. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
12. [The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
Suzuki Y; Miwa Y; Akino H; Fujita T; Saikawa S; Kanimoto Y; Okada K
Hinyokika Kiyo; 1993 Dec; 39(12):1215-20. PubMed ID: 8285172
[TBL] [Abstract][Full Text] [Related]
13. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
[TBL] [Abstract][Full Text] [Related]
14. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
16. UK studies on suramin therapy in hormone resistant prostate cancer.
Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
18. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
20. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]